Replies to post #156451 on Biotech Values

[oc631]

One more thought on the GILD C.C.



The suggestion that longer 24-week dosing might improve Sofo/Riba GT3 SVR rates is non-sense. The difference between interferon-based and oral therapy is becoming quite clear. Whereas 24-weeks of interferon-based dosing brought exceedingly higher SVR rates this is not the case going beyond 12-weeks of oral treatment.


This is nothing more than false hope being fed to analysts.

[genisi]

The Sofosbuvir/Daclatasvir oral combo demonstrated 100% SVR24 rates in GT2/GT3 patients (Phase 2 / n=14).

Note that in that phase II of sofosbuvir + daclatasvir w/wo ribavirin treatment duration was 24 weeks in GT2/3 and perhaps there were other differences like cirrhotic patients.